Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new site revision label, v3.3.4, was added and the previous revision, v3.3.3, was removed. This represents a routine background update with no changes to trial data or user-facing functionality.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now includes a new entry: Revision: v3.3.3. The footer link 'HHS Vulnerability Disclosure' and the older 'Revision: v3.3.2' have been removed.SummaryDifference0.1%

- Check60 days agoChange DetectedRecord History shows a new metadata revision (Revision: v3.3.2) added and an older revision (Revision: v3.2.0) removed; this reflects version metadata rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange Detected- Removed a prominent notice stating that information on the site may not be up to date due to government funding lapses and that the NIH Clinical Center is open, with links to cc.nih.gov and opm.gov for status updates.SummaryDifference0.3%

- Check81 days agoChange DetectedThe Record History for NCT03631199 now shows additional history entries, reflecting newer submissions and status updates.SummaryDifference0.0%

- Check110 days agoChange Detected- Added a government-operating-status notice and a link to operating status information, signaling potential delays in processing and inquiries. - Updated version to v3.2.0 and removed the previous v3.1.0 reference.SummaryDifference7%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.